Your Snoring Is Killing You. A Clinical Review of Sleep Apnea in High-Functioning Men.

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

Obstructive sleep apnea (OSA) is the collapse of the upper airway during sleep, producing repeated interruptions of normal breathing. Its prevalence in middle-aged men is estimated between 17 and 34 percent depending on the diagnostic threshold used. It is associated with systemic hypertension, cardiac arrhythmia, heart failure, stroke, and coronary artery disease. It is independently predictive of cardiovascular mortality.

It is also severely underdiagnosed, particularly in men who do not fit the clinical stereotype.

Prevalence and the Diagnostic Gap

Most clinical screening tools for sleep apnea were developed and validated in patients presenting to sleep clinics. These patients tend to be obese, loudly snoring, and excessively sleepy during the day. The STOP-BANG questionnaire, widely used for preoperative screening, includes body mass index and snoring loudness as its highest-weighted items.

The high-functioning executive at a normal weight who wakes at 3 a.m. consistently, feels unrested despite 7 hours of sleep, and snores only when he has had wine does not score highly on STOP-BANG. He is not obese. His snoring is not dramatic. His sleepiness is managed with caffeine and presented as a function of his demanding schedule.

He may have moderate to severe obstructive sleep apnea.

The diagnostic gap between population prevalence estimates and clinical diagnosis rates is large. Most estimates suggest that more than 80 percent of clinically significant OSA in adults is undiagnosed.

The Cardiovascular Mechanism

Every apnea event produces a cascade. The airway collapses. Oxygen saturation falls. The brain detects hypoxia and activates a cortical arousal, a partial awakening that restores breathing. This arousal is mediated by the sympathetic nervous system. Each arousal produces a spike in heart rate, blood pressure, and catecholamine release.

In a man with an apnea-hypopnea index (AHI) of 25, this sequence occurs 25 times per hour. Over a 7-hour sleep period, that is 175 sympathetic activations. Each produces a blood pressure surge. The normal overnight blood pressure dip, a critical cardiovascular recovery window, is abolished. The man wakes having spent the night in intermittent hypoxia with continuous sympathetic activation and calls it a bad night’s sleep.

The cardiovascular consequences accrue through several mechanisms:

Sustained sympathetic activation. The overnight catecholamine surges produce persistent daytime sympathetic elevation even after waking. This drives resting heart rate elevation and blood pressure elevation that are resistant to standard treatment.

Intermittent hypoxia and oxidative stress. Repeated cycling of oxygen desaturation and re-oxygenation generates reactive oxygen species that impair endothelial function and promote atherosclerosis.

Systemic inflammation. OSA is associated with elevated CRP, IL-6, and TNF-alpha. The inflammatory state produced by intermittent hypoxia and sleep fragmentation independently contributes to cardiovascular risk.

Endothelial dysfunction. Multiple studies document impaired flow-mediated dilation in untreated OSA patients that partially reverses with CPAP therapy. 4 / Promising

The Evidence Base

SLEEP HEART HEALTH Study

The landmark population-based cohort study, enrolling more than 6,000 adults, established that OSA is independently associated with cardiovascular disease, heart failure, and stroke after controlling for traditional cardiovascular risk factors. (Shahar et al. 2001, Am J Respir Crit Care Med) 5 / Solid

Wisconsin Sleep Cohort

The Wisconsin Sleep Cohort, a long-running community-based study, found that severe untreated OSA (AHI greater than 30) was associated with a nearly three-fold increased risk of cardiovascular mortality compared to no OSA, after adjustment for BMI, age, sex, and smoking. (Young et al. 2008, Sleep) 5 / Solid

Resistant Hypertension and OSA

A particularly important subset: men with hypertension that does not respond to multiple medications often have untreated OSA as the underlying driver. The overnight sympathetic surges continuously resist the blood pressure reduction that daytime medications achieve. Multiple studies have shown that CPAP treatment in patients with resistant hypertension produces clinically meaningful blood pressure reduction. 4 / Promising This is one of the most underrecognized and reversible causes of pharmacologically resistant hypertension.

Atrial Fibrillation: The Arrhythmia Connection

OSA is one of the strongest modifiable risk factors for atrial fibrillation (AF), and the mechanism is structural as much as electrical. During each obstructed breath, the thorax generates intense negative pressure trying to pull air past a collapsed airway. That negative intrathoracic pressure is transmitted to the cardiac chambers. The atrial walls are repeatedly stretched, and over time, the left atrium enlarges. Left atrial enlargement is one of the most reliably observed structural changes in patients with long-standing OSA, and it matters: dilated atrial tissue conducts electrical signals abnormally, creating the substrate for reentrant circuits that trigger AF.

The SLEEP HEART HEALTH Study found a 4-fold increase in AF prevalence among patients with severe OSA compared to those without OSA, even after controlling for age, BMI, and hypertension. This is not a modest association. A 4-fold increase in AF prevalence puts untreated severe OSA in the same risk category as well-established AF drivers such as heart failure and valvular disease.

The clinical consequence extends beyond the diagnosis of AF itself. A meta-analysis by Qureshi et al. found that OSA patients who underwent catheter ablation for AF had significantly higher rates of AF recurrence than patients without OSA, underscoring that ablation does not address the underlying structural remodeling that OSA drives. In contrast, CPAP treatment is associated with reduced AF recurrence rates after cardioversion, suggesting that controlling the breathing disruption can stabilize the electrical environment.

The relationship runs in both directions. AF fragments sleep through irregular heart rhythm, nocturia, and heightened sympathetic tone; disrupted sleep in turn worsens AF burden. For a man who has been told he has AF and is managing it with medication or has been through cardioversion or ablation, untreated OSA is not a separate problem to address later. It is a direct driver of the arrhythmia he is already being treated for.

The clinical question worth asking in any man with AF: has anyone ordered a sleep study? 4 / Promising

Clinical Presentation in High-Functioning Men

The presentation in the high-functioning, lean, middle-aged professional man is distinct from the classical presentation and requires a different clinical index of suspicion.

What to look for:

Morning headaches. These result from nocturnal hypercapnia (elevated CO2) and are a specific symptom of nocturnal breathing impairment.

Waking unrefreshed despite adequate sleep duration. The man sleeping 7 to 8 hours and waking fatigued consistently has a restorative sleep impairment. Sleep apnea is a leading cause.

Early morning awakening with a charged, hyperaroused quality. The 3 a.m. wakeup described throughout this site is consistent with a sympathetic surge pattern that can indicate OSA-driven nocturnal activation.

Partner-reported breathing pauses. This is the most sensitive historical finding. The partner who reports the man “stops breathing” during sleep is providing a clinical sign of apnea. Many men present without this history because they sleep alone, or because the partner has never connected the snoring pattern to a clinical concern.

Alcohol-mediated worsening. Alcohol relaxes the upper airway muscles. Men with borderline OSA who drink regularly may have significant apnea only on drinking nights and minimal apnea otherwise, making the pattern inconsistent and therefore easy to dismiss.

Diagnosis

Home sleep testing has replaced polysomnography as the appropriate first-line diagnostic study in most adults with a clinical presentation consistent with OSA. A portable sleep monitoring device, typically mailed to the patient and worn for two nights at home, measures oxygen saturation, heart rate, airflow, and respiratory effort. Results are analyzed by a sleep medicine specialist and reported as the AHI.

Home testing is accurate for the diagnosis of moderate and severe OSA in patients without complicating comorbidities (significant COPD, heart failure, or neuromuscular disease). For borderline or mild presentations, or in patients with complicating conditions, in-laboratory polysomnography remains the gold standard.

The test can be ordered by a primary care physician without specialist referral in most US health systems.

Treatment and Cardiovascular Benefit

CPAP (Continuous Positive Airway Pressure) is the most effective treatment for OSA and the treatment with the most cardiovascular evidence. CPAP prevents airway collapse by delivering pressurized air through a mask during sleep. The cardiovascular benefits documented with CPAP treatment include:

• Blood pressure reduction, particularly in patients with resistant hypertension and significant nocturnal dipping impairment 4 / Promising
• Improvement in flow-mediated dilation (endothelial function) 4 / Promising
• Reduction in daytime sympathetic tone 4 / Promising
• Improvement in cardiac arrhythmia burden, particularly nocturnal atrial fibrillation 4 / Promising

Positional therapy. Supine (back-sleeping) position significantly worsens OSA in many patients. Positional therapy devices that prevent supine sleep are effective in positional-dependent OSA. This is often an appropriate first-line intervention for mild to moderate OSA in lean patients.

Weight reduction. For overweight and obese patients, weight loss reduces OSA severity substantially and may resolve it in milder cases. A 10 percent weight reduction typically produces a 25 to 30 percent reduction in AHI.

Alcohol reduction. Eliminating late-night alcohol consumption reduces upper airway muscle relaxation and can meaningfully improve nocturnal breathing.

Mandibular advancement devices. For patients with mild to moderate OSA who cannot tolerate CPAP, mandibular advancement devices are an evidence-based alternative with documented, if smaller, cardiovascular benefit.

The AHI Threshold Question: When Does It Become Dangerous?

The AHI stratifies OSA severity into three bands: mild (AHI 5 to 14), moderate (AHI 15 to 29), and severe (AHI 30 or above). These cutoffs are clinically useful for treatment decisions, but they can create a false sense that the risk curve steps up sharply only at AHI 30. The data do not support that reading.

The Wisconsin Sleep Cohort and Sleep Heart Health Study data show that the cardiovascular risk curve begins rising in the moderate range. Men with AHI 15 to 29 carry meaningfully elevated cardiovascular risk compared to men with AHI below 5, and the risk accelerates further above AHI 30. There is no clean threshold below which OSA is safe. A man told he has “mild” sleep apnea is not being told he has no cardiovascular problem; he is being told his number is lower than someone else’s.

A more important nuance concerns what the AHI does not capture. The AHI counts breathing event frequency but says nothing about the severity of the oxygen drops those events produce. The oxygen desaturation index, which measures how often overnight oxygen saturation falls below 90 percent and by how much, may be a better predictor of cardiovascular risk than AHI alone. A man with AHI 20 but frequent desaturations to 80 to 82 percent likely carries higher cardiovascular risk than a man with AHI 25 whose oxygen never drops below 88 percent. This distinction is not always explained when home sleep test results are delivered. If you receive a sleep study result, ask specifically about your oxygen desaturation index and your minimum overnight oxygen saturation, not only your AHI.

The practical implication: moderate OSA with significant oxygen desaturations should be treated with the same seriousness as severe OSA by AHI alone. The number on the report is a starting point for the conversation, not the whole picture. 4 / Promising

CPAP Adherence: The Real-World Problem

CPAP is highly effective when used. The clinical evidence base for CPAP is substantial, and the mechanism by which it prevents cardiovascular harm is well characterized. The problem is not efficacy; it is adherence.

Clinical trials and payer standards typically define CPAP adherence as use for at least 4 hours per night on at least 70 percent of nights. Real-world data consistently show that 30 to 50 percent of patients prescribed CPAP do not meet this threshold at 12 months. The device gets used for a few nights, then ends up in the closet because the mask was uncomfortable, the pressure felt suffocating, or the man simply decided he felt fine without it.

This adherence failure has important consequences for interpreting the large randomized CPAP trials. The SAVE trial (2016, New England Journal of Medicine) and the ISAACC trial (2020) both found smaller cardiovascular benefit from CPAP than the observational cohort data had suggested. Both trials were significantly affected by low adherence in the CPAP arms. In the SAVE trial specifically, patients who used CPAP for more than 4 hours per night had significantly lower rates of cardiovascular events than low-adherence users. The benefit was present; it was being diluted by the patients who wore the mask for two hours and called it done.

This is worth understanding clearly: the large trials do not show that CPAP fails to protect the cardiovascular system. They show that CPAP worn intermittently provides intermittent protection. The cardiovascular risk of OSA runs 24 hours a day because the structural changes OSA produces, left atrial enlargement, endothelial dysfunction, elevated resting sympathetic tone, do not reverse in a week of poor adherence.

For men who have tried CPAP and abandoned it, the technology has improved substantially. Modern auto-titrating pressure (APAP) devices adjust pressure breath by breath rather than delivering a fixed high pressure all night, which many patients find more tolerable. Heated humidification eliminates the nasal dryness that is one of the most common reasons for early abandonment. Mask fitting is a skill, and many men who failed with one mask style have succeeded with a different interface. These are solvable problems, not inherent limitations of the treatment. 4 / Promising

Three Actions

1. If you are waking unrefreshed, have morning headaches, or have ever been told you snore or stop breathing during sleep, ask your primary care physician for a home sleep study. One conversation. One test.

2. If you have blood pressure that has not responded to two or three medications, raise the question of sleep apnea explicitly. Say: could untreated sleep apnea be contributing to my blood pressure? This is a question that redirects the clinical approach for a meaningful proportion of patients in this situation.

3. If you have a bed partner, ask them directly whether you snore, gasp, or pause breathing during sleep. Their answer is clinical data. Bring it to your physician.

This paper is for educational purposes and does not constitute medical advice. Discuss your individual clinical situation with your physician.